Skip to main content
Premium Trial:

Request an Annual Quote

CRUK's Commercial Branch, Abcodia Launch Cancer Biomarker Collaboration

NEW YORK (GenomeWeb News) – Cancer Research UK's commercial arm, Cancer Research Technology (CRT), will partner with the biomarker validation firm Abcodia to develop blood tests for detecting early-stage cancers, CRUK said today.

The collaborators will harness Abcodia's longitudinal biomarker profiling expertise and CRUK's scientific network. They will have access to more than five million serum samples contained in the UK Collaborative Trial for Ovarian Cancer Screening at University College London. That trial, which has taken samples from people who were healthy for as long as 10 years before some of them were diagnosed with cancer, is funded in part by CRUK.

CRT and UK-based Abcodia plan to use this sample collection to select biomarkers that provide clear indicators for changes in the early stages of disease.

They will focus their attention on markers that may be expressed in serum, such as proteins, microRNAs, DNA methylation, cell derived vesicles, and autoantibody markers, and they will investigate both genetic and acquired risk factors.

The collaborators also plan to jointly commercialize any biomarkers they discover and to share the resulting revenues with any third-party partners through license arrangements.

The Scan

Study Links Genetic Risk for ADHD With Alzheimer's Disease

A higher polygenic risk score for attention-deficit/hyperactivity disorder is also linked to cognitive decline and Alzheimer's disease, a new study in Molecular Psychiatry finds.

Study Offers Insights Into Role of Structural Variants in Cancer

A new study in Nature using cell lines shows that structural variants can enable oncogene activation.

Computer Model Uses Genetics, Health Data to Predict Mental Disorders

A new model in JAMA Psychiatry finds combining genetic and health record data can predict a mental disorder diagnosis before one is made clinically.

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.